Form 4: Fulgent Genetics CEO's Trust Cancels Major Forward Sale Agreement, Reacquires Control of 800,000 Shares

The Ming Hsieh Trust, associated with Fulgent Genetics CEO Ming Hsieh, has paid over $16.4 million to cancel a prepaid variable forward agreement, regaining control of 800,000 shares of Fulgent Genetics common stock.

Summary

• Ming Hsieh, CEO, Director, and 10% Owner of Fulgent Genetics, Inc. (FLGT), reported changes in beneficial ownership.
• The Ming Hsieh Trust, for which Mr. Hsieh is the trustee, previously entered into a prepaid variable forward agreement (the '2022 Agreement') on September 14, 2022, with an unaffiliated bank.
• This agreement obligated the Trust to deliver up to 800,000 shares of Fulgent Genetics common stock (or an equivalent cash amount) to settle the contract.
• On June 9, 2025, the Trust elected to cancel the 2022 Agreement with respect to all 800,000 shares.
• In connection with this cancellation, the Trust paid an aggregate of $16,446,960.00 to the bank.
• Following this payment and cancellation, the 800,000 shares previously subject to the prepaid forward contract are no longer pledged to the bank.
• Mr. Hsieh's direct beneficial ownership is 810,679 shares of Common Stock.
• Indirect beneficial ownership includes 7,895,115 shares held by The Ming Hsieh Trust, 220,816 shares by the Dynasty Trust, and 2,000 shares across two Uniform Transfer to Minor Accounts.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While the trust incurred a significant cash outflow, the decision to pay to regain control of a large block of shares suggests confidence in the company's future value by the CEO's associated entity.

Positives

• The cancellation of the forward sale agreement means 800,000 shares of Fulgent Genetics common stock are no longer pledged to a bank, increasing the flexibility and control of these shares for The Ming Hsieh Trust.
• This action could be interpreted as a vote of confidence by the CEO's trust in the future value of Fulgent Genetics shares, as they chose to pay a significant sum to retain ownership rather than fulfill the obligation to sell.

Negatives

• The Ming Hsieh Trust incurred a significant cash outflow of $16,446,960.00 to cancel the prepaid variable forward agreement.

Risks

• No new specific risks are introduced by this filing; however, the original forward contract was a financial instrument that carried certain risks related to stock price movements, which are now mitigated for the Trust by its cancellation.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

This Form 4 filing details a specific insider transaction by the CEO's trust and does not provide information relevant to broader industry trends or competitive landscape analysis. It is an individual financial decision by a key insider.

Stakeholder Impact

• Shareholders: The release of 800,000 shares from a forward sale contract removes a potential overhang on the stock, as these shares are no longer obligated for sale. This could be viewed positively.
• Ming Hsieh and Associated Trusts: The primary impact is on the reporting person and his trusts, who incurred a significant cash payment but regained full control over a substantial block of shares.

Key Dates

Keywords

Fulgent Genetics, FLGT, SEC Form 4, beneficial ownership, insider transaction, Ming Hsieh, forward contract, equity securities, trust, stock ownership